Dallapiccola B, Torrente I, Mingarelli R, Novelli G
Cattedra di Genetica Medica e Umana, Università Tor Vergata, Rome, Italy.
Acta Genet Med Gemellol (Roma). 1997;46(3):139-46. doi: 10.1017/s0001566000000556.
The present genome era is characterized by speedy progress and prompt transfer of results into clinical practice. This creates the need for rapid disclosure of results and renewal of laboratory's protocols. Molecular cytogenetics has provided and increased ability to identify chromosomes, correlate chromosome structure with gene location, find out cryptic aberrations, and detect specific DNA sequences. These advances have allowed the confident discovery of a number of contiguous gene syndromes. The positional cloning and positional candidate strategies have greatly expedited the search process of disease genes, and become relevant methods for genes' discovery. Understanding the molecular basis of diseases has shown an unpredicted wide genetic heterogeneity, which has splitted single disorders into many clinically similar conditions, and added complexity to the nosology of human diseases. The opposite process, allelism, where clinical diversity results from allelic mutations, has lumped together many distinct disorders, by showing that different clinical entities are not necessarily due to mutations in different genes. Dynamic mutations have provided the molecular understanding of interindividual and intrafamilial variability including anticipation, in a number of diseases. The discovery of distinct correlations between the molecular pattern and disease severity is providing a unique opportunity for using molecular results to assess the clinical outcome. Diagnostic, presymptomatic and predictive molecular testing are becoming widely used and provide enormous opportunities for improving the lot of our patients.
当前的基因组时代以快速发展以及研究成果迅速转化为临床应用为特征。这就需要快速公布研究结果并更新实验室方案。分子细胞遗传学提高了识别染色体的能力,能将染色体结构与基因定位相关联,找出隐匿性畸变并检测特定DNA序列。这些进展使得人们能够确切发现许多相邻基因综合征。定位克隆和定位候选策略极大地加速了疾病基因的搜寻过程,成为发现基因的相关方法。对疾病分子基础的认识显示出意想不到的广泛遗传异质性,这将单一疾病拆分为许多临床症状相似的病症,增加了人类疾病分类学的复杂性。相反的过程,即等位性,其中临床多样性由等位基因突变导致,它将许多不同的病症归为一类,表明不同的临床实体不一定是由不同基因的突变引起的。动态突变在许多疾病中为个体间和家族内变异性(包括早现现象)提供了分子层面的理解。分子模式与疾病严重程度之间独特关联的发现,为利用分子检测结果评估临床结局提供了难得的机会。诊断性、症状前和预测性分子检测正得到广泛应用,为改善我们患者的命运提供了巨大机遇。